New Products

May 25, 2018

Asuragen AmplideX PCR/CE DMPK Kit

Asuragen has launched the AmplideX PCR/CE DMPK Kit, a research-use-only assay designed to simplify analysis of repeat expansions in the DMPK gene, which is implicated in myotonic dystrophy type 1 (Steinert's disease). The repeat expansions in DMPK commonly extend beyond 1,000 CTG repeats and therefore have previously required the use of Southern blot technology to estimate their size, Asuragen noted, adding that its new kit is a significant improvement over this process.

May 22, 2018

SomaGenics RealSeq-Biofluids

SomaGenics has launched RealSeq-biofluids, a next-generation sequencing library construction kit sensitive for detecting small RNAs in cell-free biofluids. Based on the company's bias-free RealSeq technology, the new kit is designed to allow researchers to sequence small RNAs from as little as 50 µl of plasma or other body fluids.

May 17, 2018

Precipio KRAS Liquid Biopsy Kits for Pancreatic Cancer

Precipio has launched two new research-use only ICEme kits for the detection of mutations in KRAS Exons 2 and 3 in pancreatic cancer. The kits use the company's proprietary ICE-COLD PCR liquid biopsy technology and are available for both qPCR and Sanger sequencing platforms. According to Precipio, its non-invasive, low-cost enrichment technology is well-suited for laboratories developing screening and monitoring tests. The kits will be priced at approximately $100 per specimen.

May 17, 2018

Bluebee Bluebase Assay

Bluebee has announced the release of its Bluebase assay, which is designed to run on the Bluebee core data analysis platform and provides post-sequencing intelligent data aggregation, ease of querying, and deep knowledge mining. The technology aggregates, organizes, and stores combined genomic data sets, phenotypes, and other metadata from a group of public and private databases. Bluebase allows for a range of applications, including discovery and validation of biomarkers, insight into patient stratification approaches, cross-study analyses by multidisciplinary teams, and identification of drug candidates for clinical trials. BlueBee noted that Bluebase is targeted toward diagnostic assay developers, pharmaceutical researchers, clinical trial operators, and investigators of population-scale initiatives. 

May 16, 2018

DDN Storage/Parabricks Genomic Analysis Platform

DDN Storage and Parabricks announced the availability of a jointly integrated technology platform that massively accelerates human genome analysis. The platform DDN's high-performance Parallel Flash Data Platforms and Parabricks' DNA Bricks application to deliver a "unified genomics analysis infrastructure that provides performance, simplicity, and flexibility for end users, the companies said. The new GPU and storage solution can analyze 1,500 genomes a week, accelerating precision medicine workflows by 100x, the companies said. For example, they noted that the platform can take an industry-standard pipeline, like GATK4, and shrink run time from more than 30 hours down to mere minutes.

May 16, 2018

Veracyte Afirma Xpression Atlas

Veracyte has launched its Afirma Xpression Atlas test for thyroid cancer. The test uses RNA sequencing to analyze 761 DNA variants and 130 RNA fusions in over 500 genes that have been linked to thyroid cancer. The test's aim is to provide information to help clinicians make surgery and treatment decisions for patients who have thyroid nodules.

May 15, 2018

Invivoscribe LymphoTrack Dx TRB Assay

InvivoScribe Technologies has released its LymphoTrack Dx TRB Assay for the Illumina MiSeq platform, a CE-marked next-generation sequencing kit for in vitro diagnostic use. The assay completes the menu of Invivoscribe's CE-marked clonality assays on the MiSeq, enabling small and large laboratories to identify and track clonal rearrangements.

May 14, 2018

Interpace Diagnostics ThyGeNext

Interpace Diagnostics said it is launching ThyGenNext, a mutational panel for indeterminate thyorid nodules, at the American Association of Clinical Endocrinologists annual meeting this week. ThyGeNext builds on the company's ThyGenX panel (launched in August 2014) by adding numerous molecular markers, gene mutations, and RNA fusions, resulting in a more comprehensive set of indicators to identify malignant or benign nodules and ascertain aggressiveness and other characteristics. Specifically, it uses next-generation sequencing to identify more than 150 genetic alterations assciated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer.

May 11, 2018

Oxford Nanopore MinKnow Software

Oxford Nanopore Technologies has released an updated version of its MinKnow software, which controls its MinIon, GridIon, and PromethIon sequencing platforms. Among other changes, the new version includes a feature called "progressive unblock," which helps increase the data yield of a flow cell, and active voltage control, which improves signal consistency during a run.

May 09, 2018

Karius NGS Pathogen Test

Karius has launched a quantitative version of its next-generation sequencing-based test that identifies microbial cell-free DNA in blood. According to the company, the test can identify DNA from more than 1,000 pathogens including bacteria, DNA viruses, fungi, mold, and protozoa.

May 08, 2018

Intermountain Healthcare RxMatch Comprehensive Panel

Intermountain Precision Genomics Core Laboratory said its RxMatch Comprehensive Panel has expanded to 97 gene targets from 36. Originally launched last September as an anti-depressent panel, it now includes opioids, statins, immunosuppresants, anti-depressants, and others. Patients provide a DNA sample with a cheek swab collected in a physician's office. Results are available within about a week. Intermountain Precision Genomics Core Laboratory is part of Intermountain Healthcare.

May 04, 2018

Bio-Rad Bio-Plex Pro Human Cytokine Screening Panel

Bio-Rad Laboratories has launched the Bio-Plex Pro Human Cytokine Screening Panel, a multiplex assay that can identify and quantify 48 different analytes linked to heart disease, autoimmunity and allergy, cancer, and other conditions.

The panel detects targets related to adaptive immunity cytokines, pro-inflammatory cytokines, and anti-inflammatory cytokines, all in a single well. It is available in a 96-well kit format that includes premixed magnetic capture beads and detection antibodies, multiplexed standards and controls, secondary antibodies for fluorescence detection, and buffers. The panel is compatible with the Bio-Plex MAGPIX Multiplex Reader, Bio-Plex 200 and Bio-Plex 3D Multiplex Immunoassay Systems, LX200 Instrument, and Flexmap 3D System, and data can be managed and analyzed using Bio-Plex Manager and Bio-Plex Data Pro Software.

May 02, 2018

PredicineATLAS

Predicine has launched a new liquid biopsy panel called PredicineATLAS, which covers 600 genes and offers a readout of patients tumor mutational burden to help inform and assess immuno-oncology treatment.

The assay will be available first for research use only though an early access program, but the company aims to at some point add a CLIA-certified version as well.

Apr 26, 2018

Agilent In Situ Hybridization Probes

Agilent Technologies introduced a number of in situ hybridization probes, including the EBER RNA CISH, Kappa, and Lambda mRNA CISH probes for Dako Omnis. Additionally, a manual IQFISH panel for lymphoma was launched following its CE marking. 

The EBER RNA CISH, Kappa, and Lambda mRNA CISH releases increase the diagnostic capabilities of the Dako Omnis instrument, which can now be used to simultaneously run tests involving CISH, FISH, and immunohistochemistry. Meanwhile, the IQFISH panel is a set of oligonucleotide-based FISH probes for detecting rearrangements involving the MYC, CBL2, BCL6, MALT1, CCND1, and IGH genes. The probes are for use on formalin-fixed, paraffin-embedded tissue sections, Agilent said, adding they are available in break-apart and dual-fusion methodologies.

Apr 25, 2018

HiberGene HG Pneumo/Meningo Combo

HiberGene has launched the HG Pneumo/Meningo Combo test for the rapid detection of meningococcal and pneumococccal meningitis. The loop-mediated isothermal amplification-based test covers up to 90 percent of cases of bacterial meningitis and provides results in less than one hour, compared to traditional microbiological methods which can take between 24 and 48 hours, the company said. Samples are incubated and read on HiberGene's HG Swift instrument. 

Apr 23, 2018

Swift Biosciences Accel-Amplicon Plus Cancer NGS Panels

Swift Biosciences has launched a suite of nine tumor-specific gene panels using its Accel-Amplicon technology. The Accel-Amplicon Plus Cancer NGS Panels enable detection of SNVs, copy number variants, and small indels. The company has launched four disease-focused panels for colorectal cancer, Lynch syndrome, lung cancer, and myeloid malignancies. In addition, it has also launched five gene panels, including one that focuses on comprehensive coverage of the TP53 gene, two BRCA-focused panels, an EGFR panel, and a pan-cancer panel. The panels are compatible with Illumina's sequencing instruments. Just 10 nanograms of sample input are required, and sample inputs can include DNA from formalin-fixed paraffin-embedded tissue and fine needle aspirates, as well as cell-free DNA. In addition, Swift has also launched its Swift Bioinformatics Resources, which include both open source and commercial bioinformatics tools to analyze NGS data.

Apr 23, 2018

Siemens Healthineers Fast Track Cycler, FastFinder Software

Fast Track Diagnostics, a Siemens Healthineers company, launched the Fast Track Cycler molecular testing platform and complementary FastFinder software at the European Congress of Clinical Microbiology and Infectious Diseases. 

The Fast Track cycler, for research use only, is a compact thermocycler weighing about 2 kg and measuring about 150mm3. It uses magnetic induction technology and does not require calibration. It also is equipped with Fast Track lyophilized PCR reagents, enabling users to simply add nucleic acid extracts to prepared tubes before placing them in the cycler. Up to 10 thermocyclers can be connected to one computer, and labs can use a range of one to 480 wells.

The FastFinder software, developed in collaboration with UgenTec, is a fully automated, CE IVD-marked real-time PCR interpretation platform compatible with all Fast Track multiplexed PCR kits. The software allows users to fully automate and standardize analysis of kits on the Thermo Fisher Scientific ABI 7500 and Roche LightCycler 480 PCR platforms. The software features statistical machine learning to accurately analyze all amplications curves, automatically recombining the results and processing them through an assay-specific decision tree to product a final result.

Apr 23, 2018

Cytena x.sight Single-Cell Printers

Cytena has launched three new single-cell printers, called c.sight, f.sight, and b.sight, that are part of its x.sight line of instruments. The c.sight instrument is designed for cell line development and single-cell genomics and can be operated outside a sterile bench. The f.sight device has two cameras, which can be controlled independently, to capture bright field and fluorescence signals simultaneously. In addition, it has an adjustable laser. The b.sight system enables the isolation of cells in the sub-micron range and printing single-cell bacteria. It has high-resolution optics and requires no staining or labeling of the cells. Cytena has also updated the software for all its single-cell printers, allowing them to be integrated into robotic platforms.

Apr 23, 2018

Qiagen QiaStat-Dx

Qiagen announced the European launch of the QiaStat-Dx platform during the European Congress of Clinical Microbiology and Infectious Diseases in Madrid. The company also launched the first test on the system, a 21-pathogen respiratory panel. QiaStat-Dx is a fully integrated and automated molecular testing system based on real-time PCR. It can detect up to 48 viral and bacterial targets simultaneously, enabled by microfluidic test casettes coupled with a six-wavelength optical sensor. There are also plans for the instrument to run immunoassays based on time-resolved fluorescence detection. The system, previously developed by StatDx as the DiagCore, received CE marking in January, prior to Qiagen's acquisition of StatDx.

Apr 19, 2018

Horizon Discovery Edit-R CRISPRa crRNA Libraries

Horizon Discovery announced the introduction of its Edit-R CRISPR arrayed crRNA (CRISPR RNA) libraries, which offer a tool for drug discovery, pathway analysis and disease progression studies. The libraries allow one-gene-per-well investigation by using high-content assays. The Edit-R CRISPRa portfolio also includes catalogue libraries for human and mouse gene families, including ubiquitin enzymes, transcription factors, and kinases, in addition to druggable gene targets and the whole human genome. The firm also noted that researchers will also be able to use bespoke collections to target a specialized gene target list.  

Apr 17, 2018

Bio-Techne RNAscope Assays

Bio-Techne announced the launch of its RNAscope VS Duplex kit, which delivers simultaneous in situ detection of two RNA species on an automated platform. The assay enables experiments including co-localization studies and gene expression profiling in specific cell types identifiable with known markers. The assay delivers improved specificity and sensitivity with clean signals, allowing researchers to pinpoint gene expression at single-molecule sensitivity.

In addition, Bio-Techne has launched the RNAScope VS Universal HRP and AP assays, which will integrate with Roche's mRNA universal software. The assays also have protocols that allow dual staining with immunohistochemistry or immunofluorescence.

Bio-Techne has also released the updated RNAscope 2.5 VS Reagent Kit-BROWN and -RED assays, which deliver permanent and intensified staining. The firm claims the assays are suitable for archiving and are ideal when anticipating low copy target gene expression.

Apr 17, 2018

Mission Bio Tapestri, Panels

Mission Bio has updated its Tapestri single-cell DNA analysis platform, which is now compatible with the Illumina HiSeq 2500 sequencer to allow for multiplexing and larger panels.

The company has also launched two new panels for myeloid disorders and for solid tumor profiling. The Tapestri Single-Cell DNA Myeloid Panel, designed to cover several myeloid disorders, targets single-nucleotide variants and indels in 47 genes. The Tapestri Single-Cell Tumor Hotspot Panel targets SNV and indel hotspot mutations across 50 genes involved in different solid tumor types and has been tested with breast, lung, prostate, and colorectal cancer nuclei from fresh-frozen tissue samples.

Apr 16, 2018

Thermo Fisher Scientific Oncomine Childhood Cancer Research Assay

Thermo Fisher Scientific has launched the Oncomine Childhood Cancer Research Assay, a next-generation sequencing panel developed in collaboration with Children's Hospital Los Angeles that specifically targets mutations associated with pediatric and young adult cancers. The assay combines specific mutations, gene amplifications, and fusions over 203 genes representing multiple gene classes, and 1,700 fusion transcripts in two DNA and two RNA pools. The assay is designed to integrate with the Ion Chef system for automated library preparation and amplification, as well as the Ion GeneStudio S5 system and Ion Reporter for bioinformatics and reporting.

Apr 16, 2018

True Health PlanTrue

True Health has launched the PlanTrue genetic carrier screening test. The next-generation sequencing test analyzes up to more than 80 genes associated with early-onset genetic conditions that are both prevalent and actionable. It comes in five versions that cover between three and 82 genetic conditions.

Apr 13, 2018

Fluidigm Maxpar Human Immune Monitoring Panel Kit

Fluidigm has launched the Maxpar Human Immune Monitoring Panel Kit for comprehensive immune cell profiling in cancer and immune-mediated diseases. Designed for use with the company's Helios CyTOF mass cytometry system, the new kit contains 29 metal-labeled antibodies and reagents designed and optimized for deep immune profiling of human peripheral blood mononuclear cells in a single tube. The panel biomarkers were selected in collaboration with pharmaceutical companies and academic institutions, and are optimized for routine high-parameter immune profiling, Fluidigm said. Multiple third-party data-analysis options are available to analyze results from the panel, including Cytobank and GemStone software. Verity Software House is providing free access to an enhanced version of GemStone software to customers who purchase the kit.

Pages

Women with breast or ovarian cancer living in medically underserved regions of the US are less likely to get recommended BRCA1 or BRCA2 genetic testing, according to a new study.

Three immunology researchers are to receive this year's Albany Medical Center Prize in Medicine and Biomedical Research, the Albany Times-Union reports.

In Genome Research this week: clonal evolution analysis of acute myeloid leukemia, computational pipeline to examine relationships between bacterial pathogens, and more.

Elephants may have "re-animated" a pseudogene to help stave off cancer, according to the New York Times.